Abstract. Metabolic syndrome is a major risk factor for cardiovascular disease and atrial fibrillation. This original study included 40 patients with metabolic syndrome complicated by atrial fibrillation and aimed to assess clinical, metabolic, and hemostatic risk factors. All patients underwent evaluation of body mass index, blood pressure, glucose tolerance, and electrocardiography. Laboratory assessment included lipid profile analysis, 24-hour urinary adrenaline and noradrenaline excretion, and evaluation of hemostatic parameters. Risk stratification was performed using the CHA₂DS₂-VASc, CHARGE-AF, and HAS-BLED scores. High thromboembolic risk (CHA₂DS₂-VASc ≥2) was identified in 80% of patients, high atrial fibrillation risk according to CHARGE-AF in 70%, and increased bleeding risk in 15%. Significant associations were observed between metabolic syndrome components and atrial fibrillation risk. Comprehensive assessment allows individualized management and prevention of complications.